Ascentage Pharma Group International vs Bicycle Therapeutics
Ascentage Pharma Group International and Bicycle Therapeutics are similar in size: $79.9m and $72.6m of revenue in their latest fiscal years. Bicycle Therapeutics grew faster (105.8% against -41.4%). Ascentage Pharma Group International kept more of each dollar of sales as profit: a net margin of -216.5% against -301.7%. Bicycle Therapeutics carries less debt relative to equity (0.0% against 150.1%).
| Latest fiscal year | Ascentage Pharma Group InternationalAAPG, 2025 | Bicycle TherapeuticsBCYC, 2025 |
|---|---|---|
| Revenue | $79.9m | $72.6m |
| Revenue growth | -41.4% | 105.8% |
| Net income | −$173m | −$219m |
| Operating margin | — | -340.4% |
| Net margin | -216.5% | -301.7% |
| Return on equity | -153.3% | -31.2% |
| Free cash flow | −$167m | −$252m |
| Cash | $171m | $628m |
| Total debt | $284m | $0 |
| Debt to equity | 150.1% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $1.3m | — |
| Employees | — | 288 |
| Market value | $1.26bn | $255m |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 0 buys, 0 sales |